CN101618103A - Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis - Google Patents
Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis Download PDFInfo
- Publication number
- CN101618103A CN101618103A CN 200810116116 CN200810116116A CN101618103A CN 101618103 A CN101618103 A CN 101618103A CN 200810116116 CN200810116116 CN 200810116116 CN 200810116116 A CN200810116116 A CN 200810116116A CN 101618103 A CN101618103 A CN 101618103A
- Authority
- CN
- China
- Prior art keywords
- parts
- hour
- standby
- cortex
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of a Chinese medicinal composition in preparing a medicament for treating chronic glomerulonephritis. The Chinese medicinal composition consists of eight gouts of Chinese medicaments such as astragalus root, steatite, selfheal, and the like. The medicinal composition has the efficacies of promoting qi transformation, promoting diuresis and softening hardness to dissipate stagnation. The clinical research shows that the Chinese medicinal composition can effectively treat the chronic glomerulonephritis.
Description
Technical field
The present invention relates to a kind of new purposes of Chinese medicine composition, particularly, relate to the application of a kind of Chinese medicine composition in preparation treatment chronic glomerulonephritis medicine.
Background technology
Chronic glomerulonephritis (chronic glomerulonephritis CGN) means that the bilateral glomerule diffusivity of the different pathological types that the various causes of disease cause or focal inflammation change, clinical onset concealment, the course of disease is tediously long, and the multiple exhibition of the state of an illness is the general name of one group of primary glomerulopathy slowly.
Chronic nephritis is that the chronic glomerulus pathological changes of one group of multi-pathogenesis is main renal glomerular disease, but most of patients etiology unknown, there is no definite relation with streptococcal infection, only 15-20% changes and arrives from acute glomerulonephritis according to statistics, most of chronic nephritis patient does not have the acute nephritis medical history, so think at present no sure related between chronic glomerulonephritis and the acute nephritis, it may be owing to various antibacterials, virus or protozoan infection cause primary disease by immunologic mechanism, the inflammatory mediator factor and non-immunologic mechanism etc. more.
Chronic glomerulonephritis pathological change and the cause of disease, the course of disease are different and different with type.Can show as the increment of diffusivity or focal sections mesentery, film propagation, film, minute lesion, focal sclerosis, late period glomerule fibrosis maybe can not finalize the design.Except that the glomerule pathological changes, still can be with matter inflammation and fibrosis between kidney in various degree, the matter infringement has increased the weight of renal function injury between kidney.Glomerulonephritis renal cortex attenuation in late period, the atrophy of glomerular capillary loop develop into vitreous degeneration or fibrosis, but remaining glomerule compensatory increases renal tubules atrophy etc.
The chronic glomerulonephritis clinical manifestation, great majority concealment onset, the course of disease is tediously long, the many slowly progress of the state of an illness.Because different pathological types, clinical manifestation is inconsistent, and for appearing symptom for the first time, weight differs most cases with edema.The lighter only face and lower limb is little swollen, and nephrotic syndrome can appear in weight person, and the case that has then is found to be chronic glomerulonephritis with hypertension for appearing symptom for the first time.Also can show as asymptomatic albuminuria and/or hematuria.Or polyuria and nocturia only appear, or the whole course of disease do not have obvious muscle power go down until occur serious anemia or uremia for first symptom (Chen Haozhu. practical internal medicine. People's Health Publisher .P1810).
Motherland's medical science is under the jurisdiction of it sick scopes such as " edema ", " lumbago ", " hematuria " respectively according to the difference of chronic glomerulonephritis symptom.Successive dynasties, the physician thought, chronic glomerulonephritis belongs to deficiency in origin and excess in superficiality card, deficiency in origin refer to lung, spleen, kidney three dirty lose empty, and the most important to suffer from a deficiency of the kidney.Mark refers in fact that diseases caused by exogenous pathogenic factor, water are wet, damp and hot, turbid damp, blood stasis etc.All multifactor combineds effect cause lung to lose logical accent, dysfunction of the spleen in transportation, kidney and lose and open entire, functioning of bladder and have no right, and certainly show disrespect on mistake department, and water liquid stops gathering, and spreads unchecked skin and forms edema.In recent years, Chinese medicine is at primary disease, and dialectical executing controlled, obtained preferably curative effect (Li Caihong. the traditional Chinese medical science progress of chronic glomerulonephritis. Chinese the 19th the 9th phase of volume of primary health care .2005 JIUYUE .).
The present invention is the improvement invention of carrying out on the basis of Chinese patent ZL 200410091455.5, quotes in full the content of this patent document record at this.Chinese patent ZL 200410091455.5 does not put down in writing the application of this Chinese medicine composition in preparation treatment chronic glomerulonephritis medicine.
Summary of the invention
The object of the invention provides the application of a kind of Chinese medicine composition in preparation treatment chronic glomerulonephritis medicine;
Chinese medicine of the present invention can be had the Chinese medicine of same or similar effect fruit to replace, and these medical materials all can be concocted according to " national Chinese medicine processing standard " or " Chinese medicine voluminous dictionary ".
Described Chinese medicine composition is made by following bulk drugs:
Radix Astragali 30-150 part Talcum 7-28 part Spica Prunellae 10-40 part Fructus Ligustri Lucidi 7-28 part
Semen Litchi 10-40 part succinum 1-4 part Cortex Cinnamomi 1.5-6 part Cortex Phellodendri 3-15 part.
Preferably, described Chinese medicine composition is made by following bulk drugs:
14 parts of 21 parts of Fructus Ligustri Lucidi of 14 parts of Spica Prunellaes of 70 parts of Talcums of the Radix Astragali
7 parts of 2.8 portions of Cortex Phellodendris of 2.1 portions of Cortex Cinnamomis of 21 parts of succinums of Semen Litchi.
Or:
7 parts of 10 parts of Fructus Ligustri Lucidi of 7 parts of Spica Prunellaes of 30 parts of Talcums of the Radix Astragali
3 parts of 1.5 portions of Cortex Phellodendris of 1 portion of Cortex Cinnamomi of 10 parts of succinums of Semen Litchi.
Or:
18 parts of 19 parts of Fructus Ligustri Lucidi of 12 parts of Spica Prunellaes of 34 parts of Talcums of the Radix Astragali
13 parts of 4.5 portions of Cortex Phellodendris of 2.5 portions of Cortex Cinnamomis of 25 parts of succinums of Semen Litchi.
Or:
28 parts of 10 parts of Fructus Ligustri Lucidi of 28 parts of Spica Prunellaes of 30 parts of Talcums of the Radix Astragali
15 parts of 1.5 portions of Cortex Phellodendris of 4 portions of Cortex Cinnamomis of 10 parts of succinums of Semen Litchi.
The active component of Chinese medicine composition of the present invention can be made by the extraction process of routine [as model Bi Ting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition)], and more preferably, the active component of described Chinese medicine composition is made by the following step:
(1), take by weighing Chinese crude drug, clean respectively, pulverize by the crude drug part by weight;
(2), get the Radix Astragali, Cortex Phellodendri, add 50-70% ethanol, heating and refluxing extraction 1-3 time, each 0.5-2 hour, extracting liquid filtering merges, and behind the decompression recycling ethanol, is condensed into the clear paste that relative density is 1.20-1.25, and was standby;
(3), get Fructus Ligustri Lucidi, add 6-10 and doubly measure 70-90% ethanol, heating and refluxing extraction 1-3 time, the time is each 1-3 hour, extracting solution filters, and merges, and behind the decompression recycling ethanol, is condensed into the clear paste that relative density is 1.20-1.25, and is standby;
(4), get Cortex Cinnamomi, add 4-8 times of water gaging and soak after 1-2 hour, extracted volatile oil 2-6 hour, volatile oil device is in addition collected, aqueous extract filters to be collected, residue is standby;
(5), to get Spica Prunellae, Semen Litchi and step (4) residue obtained, adds 8-10 times of water gaging, decocts twice, 1-3 hour for the first time, 1-2 hour for the second time, extracting liquid filtering merged, add step (4) obtained aqueous solution, be condensed into the clear paste that relative density is 1.20-1.25, standby;
(6), get Talcum, succinum, be ground into 100 order fine powders, standby;
Step (2) gained clear paste, step (3) gained clear paste, step (4) gained volatile oil, step (5) gained clear paste and step (6) gained fine powder constitute the active component of Chinese medicine composition of the present invention jointly.
The preparation formulation of Chinese medicine composition of the present invention is capsule, tablet, oral liquid or pill.
The present invention also provides the preparation method of this Chinese medicinal composition capsules agent:
(1), take by weighing Chinese crude drug, clean respectively, pulverize by the crude drug part by weight;
(2), get the Radix Astragali, Cortex Phellodendri, add 50-70% ethanol, heating and refluxing extraction 1-3 time, each 0.5-2 hour, extracting liquid filtering merged, and behind the decompression recycling ethanol, is condensed into the clear paste that relative density is 1.20-1.25, vacuum drying, dried cream is standby;
(3), get Fructus Ligustri Lucidi, add 6-10 and doubly measure 70-90% ethanol, heating and refluxing extraction 1-3 time, the time is each 1-3 hour, extracting solution filters, and merges, and behind the decompression recycling ethanol, is condensed into the clear paste that relative density is 1.20-1.25, vacuum drying, dried cream is standby;
(4), get Cortex Cinnamomi, add 4-8 times of water gaging and soak after 1-2 hour, extracted volatile oil 2-6 hour, volatile oil device is in addition collected, aqueous extract filters to be collected, residue is standby;
(5), it is residue obtained to get Spica Prunellae, Semen Litchi and step (4), add 8-10 times of water gaging, decoct twice, 1-3 hour for the first time, 1-2 hour for the second time, extracting liquid filtering, merge, add step (4) obtained aqueous solution, be condensed into the clear paste that relative density is 1.20-1.25, vacuum drying, it is standby that institute gets dry extract and gets dry extract with step (2), step (3) mixed powder that gets dry extract is broken into 100 order powder;
(6), get Talcum, succinum, be ground into 100 order powder, standby;
(7), with step (5) gained dried cream powder, step (6) gained fine powder and appropriate amount of auxiliary materials mix homogeneously, be binding agent with 80% ethanol, granulate oven dry, granulate;
(8), sift out fine powder, spray into step (4) gained volatile oil, airtight, encapsulated with the granule mix homogeneously, promptly.
In the Chinese medicine composition of the present invention, as the latin name of the crude drug of active component and processing method thereof from " Chinese medicine voluminous dictionary " (in July, 1977, front page, Shanghai science tech publishing house) and " Chinese pharmacopoeia (version in 2005, Chemical Industry Press).
Chinese medicine composition of the present invention can also be routinely preparation process, for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record makes the acceptable any conventional dosage form of pharmaceutics, for example capsule, tablet, oral liquid or pill etc.
In the application of the present invention, the preparation formulation of described Chinese medicine composition is capsule, tablet, oral liquid or pill, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
For illustrating the activity of traditional Chinese medicine composition for treating chronic glomerulonephritis of the present invention, with having carried out following test by the prepared medicine of embodiment 1 method (to call medicine of the present invention in the following text).
1 clinical data
1.1 diagnostic criteria
(1) Western medicine diagnose standard: 1. onset is slow, state of an illness delay, clinical manifestation can gently can weigh, or the time heavy when light.Along with PD, can there be situations such as renal function goes down, anemia, electrolyte disturbance to occur.2. a kind of (as the hematuria or the albuminuria) of performance such as edema, hypertension, albuminuria, hematuria, cylinderuria or several can be arranged, and clinical manifestation is varied, sometimes can be with nephrotic syndrome or severe hypertension disease.3. in the course of disease nephritis acute attack can be arranged, often bring out the performance of similar sometimes acute nephritis during outbreak because of infecting (as respiratory tract infection).Some case can be alleviated automatically, and some case the state of an illness occurs and increases the weight of.But should except collagenosis, diabetic nephropathy, gouty disease, essential hypertension, renal vascular hypertension disease, pyelonephritis, orthostatic hypotension, toxic nephrosis and other as primary aldosteronism, amyloidosis, polycystic kidney, the nephropathy etc. of being pregnent well.
Possess 1.+3. or 2.+3. and can make a definite diagnosis.But serum creatinine＞442 μ mol/L do not include the observation case in.
(2) the Chinese medical discrimination typing carries out typing with reference to the related standards in " Chinese medicine (new drug) clinical research guideline ".
1.2 physical data
This patient who 86 examples is met diagnostic criteria is divided into treatment group 44 example and matched group 42 examples according to randomization, and all patients all follow up a case by regular visits to through Hebei Yi Ling hospital outpatient and hospitalization and through leaving hospital.Treatment is organized in 44 examples, male's 25 examples, women's 19 examples; Age 13-47 year, average out to (30.85 ± 11.57) year; Course of disease 1.5-19, average out to (9.56 ± 4.68) year.In matched group 42 examples, male's 22 examples, women's 20 examples; Age 14-46 year, average out to (31.63 ± 10.86) year; Course of disease 2-18, average out to (10.42 ± 3.88) year.Two groups of physical data are learned processing difference is not by statistics had significance meaning (P＞0.05), has comparability.
2 methods
2.1 Therapeutic Method
Matched group: adopt prednisone 1mg/kgd, morning 1 decoction being taken at a draught, 8 weeks of logotype, decrement gradually, decrement 10% is to maintenance dose weekly.The infected is arranged, control infection, but avoid using the renal damage medicine; The hypertension patient is arranged, select ACEI preparation or calcium antagonist and high quality protein diet etc. for use.
Treatment group: on the matched group basis, add medicine of the present invention, each 3-4 grain, every day 3 times.
Two groups was a course of treatment with two months all, and overview is added up curative effect after one course of treatment.
2.2 observation index
Main clinical effectiveness and the curative effect between the different pattern of syndrome of observing Drug therapy chronic glomerulonephritis of the present invention compares; Observe the situation of change of two groups of treatment front and back twenty-four-hour urine protein quantifications, plasma albumin, blood urea nitrogen and serum creatinines.
2.3 (x ± s) expression adopts the t check to the statistical method The data.
2.4 criterion of therapeutical effect is drafted with reference to the related standards in " Chinese medicine (new drug) clinical research guideline ".
Alleviate fully: symptom and sign complete obiterations such as edema, urine protein examination continues negative, or the twenty-four-hour urine protein quantification is lasting less than 0.2g, and urine erythrocyte disappears under the high power lens, and Urine sediments analyzer counting and renal function are normal;
The basic alleviation: symptoms such as edema disappear substantially with sign, and the urine protein examination continuous decrease is more than 50%, and urine erythrocyte is no more than 3 under the high power lens, and the Urine sediments analyzer counting is near normal, and renal function is (differ with normal value be no more than 15%) normally or substantially normally;
Take a turn for the better: symptoms such as edema are clearly better with sign, and 1+number of urine protein examination continuous decrease or twenty-four-hour urine protein quantification continuous decrease are more than 25%, and urine erythrocyte is no more than 5 under the high power lens, and renal function normally or improvement arranged;
Invalid: clinical symptoms and above-mentioned experimental check result all do not have the obvious improvement or the person of increasing the weight of.
3 therapeutic outcomes
3.1 two groups of treatment total effective rates (seeing Table 1)
Table 1 liang group therapeutic outcome and curative effect comparative example (%)
Annotate: compare with matched group,
*P＜0.01,
*P＜0.05.
Can be drawn by last table, compare with matched group, total remission rate and total effective rate all have significant difference, show that treatment group curative effect obviously is better than matched group.
3.2 the hematuria changes of biochemical indexes compares (seeing Table 2) before and after two groups of treatments
Hematuria changes of biochemical indexes comparison before and after the table 2 liang group treatment (x ± s)
Annotate: relatively preceding with the treatment of this group,
*P＜0.05 is with comparison after the treatment of control group, #P＜0.05.
Can draw by last table, compare after each group treatment with before the treatment, P＜0.05, the content of the former urine protein quantitation in front and back, plasma albumin, serum creatinine and blood urea nitrogen has significant difference.Compare after the treatment of treatment group with after the treatment of control group, P＜0.05, the content of former urine protein quantitation, plasma albumin, serum creatinine and blood urea nitrogen has significant difference, shows that treatment group curative effect obviously is better than matched group.
4, conclusion
In sum, medicine of the present invention can effectively be treated chronic glomerulonephritis, and does not have obvious adverse reaction.
The specific embodiment
Embodiment 1: the preparation of medicine capsule of the present invention
Prescription:
The Radix Astragali 70 gram Talcums 14 gram Spica Prunellaes 21 gram Fructus Ligustri Lucidi 14 grams
Semen Litchi 21 gram succinums 2.1 gram Cortex Cinnamomis 2.8 gram Cortex Phellodendris 7 grams
Preparation method:
(1), take by weighing Chinese crude drug, clean respectively, pulverize by recipe quantity;
(2), get the Radix Astragali, Cortex Phellodendri, add 60% ethanol, heating and refluxing extraction 2 times, for the first time add 10 times of amounts, extracted 2 hours, add 8 times of amounts for the second time, extracted 1 hour, extracting liquid filtering merges, behind the decompression recycling ethanol, be condensed into the clear paste that relative density is 1.20-1.25, put into vacuum drying oven, 65 ℃ of temperature, drying under reduced pressure under the vacuum 0.05Mpa condition, dried cream is standby;
(3), get Fructus Ligustri Lucidi, add 8 times of amount 80% ethanol, heating and refluxing extraction 2 times, the time is each 2 hours, extracting solution filters, merge, behind the decompression recycling ethanol, be condensed into the clear paste that relative density is 1.20-1.25, put into vacuum drying oven, 65 ℃ of temperature, drying under reduced pressure under the vacuum 0.05Mpa condition, dried cream is standby;
(4), get Cortex Cinnamomi, add 6 times of water gagings and soak after 1 hour, extracted volatile oil 4 hours, volatile oil device is in addition collected, aqueous extract filters to be collected, residue is standby;
(5), to get Spica Prunellae, Semen Litchi and step (4) residue obtained, adds 9 times of water gagings, decoct twice, 2 hours for the first time, 1.5 hours for the second time, extracting liquid filtering merged, add step (4) obtained aqueous solution, be condensed into the clear paste that relative density is 1.20-1.25, put into vacuum drying oven, 65 ℃ of temperature, drying under reduced pressure under the vacuum 0.05Mpa condition, it is standby that institute gets dry extract and gets dry extract with step (2), step (3) mixed powder that gets dry extract is broken into 100 order powder;
(6), get Talcum, succinum, be ground into 100 order powder, standby;
(7), with step (5) gained dried cream powder, step (6) gained fine powder and appropriate amount of auxiliary materials mix homogeneously, be binding agent with 80% ethanol, granulate oven dry, granulate;
(8), sift out fine powder, spray into step (4) gained volatile oil, airtight, encapsulated with the granule mix homogeneously, promptly.
Embodiment 2: the preparation of medicinal tablet of the present invention
Prescription:
The Radix Astragali 30 gram Talcums 7 gram Spica Prunellaes 10 gram Fructus Ligustri Lucidi 7 grams
Semen Litchi 10 gram succinums 1 gram Cortex Cinnamomi 1.5 gram Cortex Phellodendris 3 grams
Preparation method:
(1), take by weighing Chinese crude drug, clean respectively, pulverize by recipe quantity;
(2), get the Radix Astragali, Cortex Phellodendri, add 60% ethanol, heating and refluxing extraction 2 times adds for the first time 9 times of amounts, extracted 3 hours, and added 8 times of amounts for the second time, extracted extracting liquid filtering 1.5 hours, merge, behind the decompression recycling ethanol, be condensed into the clear paste that relative density is 1.20-1.25, standby;
(3), get Fructus Ligustri Lucidi, add 7 times of amount 80% ethanol, heating and refluxing extraction 2 times, the time is each 2 hours, extracting solution filters, and merges, and behind the decompression recycling ethanol, is condensed into the clear paste that relative density is 1.20-1.25, and is standby;
(4), get Cortex Cinnamomi, add 6 times of water gagings and soak after 1.5 hours, extracted volatile oil 5 hours, volatile oil device is in addition collected, aqueous extract filters to be collected, residue is standby;
(5), to get Spica Prunellae, Semen Litchi and step (4) residue obtained, adds 9 times of water gagings, decocts twice, 2 hours for the first time, 1.5 hours for the second time, extracting liquid filtering merged, add step (4) obtained aqueous solution, be condensed into the clear paste that relative density is 1.20-1.25, standby;
(6), get Talcum, succinum, be ground into 100 order fine powders, standby;
(7), formulation method is made tablet routinely.
Embodiment 3: the preparation of medicine oral liquid of the present invention
Prescription:
The Radix Astragali 34 gram Talcums 12 gram Spica Prunellaes 19 gram Fructus Ligustri Lucidi 18 grams
Semen Litchi 25 gram succinums 2.5 gram Cortex Cinnamomis 4.5 gram Cortex Phellodendris 13 grams
Preparation method: formulation method is made oral liquid routinely.
Embodiment 4: the preparation of bolus of drug of the present invention
Prescription:
The Radix Astragali 30 gram Talcums 28 gram Spica Prunellaes 10 gram Fructus Ligustri Lucidi 28 grams
Semen Litchi 10 gram succinums 4 gram Cortex Cinnamomis 1.5 gram Cortex Phellodendris 15 grams
Preparation method: formulation method is made pill routinely.
Claims (8)
1, the application of a kind of Chinese medicine composition in preparation treatment chronic glomerulonephritis medicine is characterized in that described Chinese medicine composition is to be made by the crude drug of following weight portion ratio:
Radix Astragali 30-150 part Talcum 7-28 part Spica Prunellae 10-40 part Fructus Ligustri Lucidi 7-28 part
Semen Litchi 10-40 part succinum 1-4 part Cortex Cinnamomi 1.5-6 part Cortex Phellodendri 3-15 part.
2, application as claimed in claim 1 is characterized in that described Chinese medicine composition is to be made by the crude drug of following weight portion ratio:
14 parts of 21 parts of Fructus Ligustri Lucidi of 14 parts of Spica Prunellaes of 70 parts of Talcums of the Radix Astragali
7 parts of 2.8 portions of Cortex Phellodendris of 2.1 portions of Cortex Cinnamomis of 21 parts of succinums of Semen Litchi.
3, application as claimed in claim 1 is characterized in that described Chinese medicine composition is to be made by the crude drug of following weight portion ratio:
7 parts of 10 parts of Fructus Ligustri Lucidi of 7 parts of Spica Prunellaes of 30 parts of Talcums of the Radix Astragali
3 parts of 1.5 portions of Cortex Phellodendris of 1 portion of Cortex Cinnamomi of 10 parts of succinums of Semen Litchi.
4, application as claimed in claim 1 is characterized in that described Chinese medicine composition is to be made by the crude drug of following weight portion ratio:
18 parts of 19 parts of Fructus Ligustri Lucidi of 12 parts of Spica Prunellaes of 34 parts of Talcums of the Radix Astragali
13 parts of 4.5 portions of Cortex Phellodendris of 2.5 portions of Cortex Cinnamomis of 25 parts of succinums of Semen Litchi.
5, application as claimed in claim 1 is characterized in that described Chinese medicine composition is to be made by the crude drug of following weight portion ratio:
28 parts of 10 parts of Fructus Ligustri Lucidi of 28 parts of Spica Prunellaes of 30 parts of Talcums of the Radix Astragali
15 parts of 1.5 portions of Cortex Phellodendris of 4 portions of Cortex Cinnamomis of 10 parts of succinums of Semen Litchi.
6, according to each described application of claim 1-5, it is characterized in that the active component of this Chinese medicine composition is made by following steps:
(1), take by weighing Chinese crude drug, clean respectively, pulverize by the crude drug part by weight;
(2), get the Radix Astragali, Cortex Phellodendri, add 50-70% ethanol, heating and refluxing extraction 1-3 time, each 0.5-2 hour, extracting liquid filtering merges, and behind the decompression recycling ethanol, is condensed into the clear paste that relative density is 1.20-1.25, and was standby;
(3), get Fructus Ligustri Lucidi, add 6-10 and doubly measure 70-90% ethanol, heating and refluxing extraction 1-3 time, the time is each 1-3 hour, extracting solution filters, and merges, and behind the decompression recycling ethanol, is condensed into the clear paste that relative density is 1.20-1.25, and is standby;
(4), get Cortex Cinnamomi, add 4-8 times of water gaging and soak after 1-2 hour, extracted volatile oil 2-6 hour, volatile oil device is in addition collected, aqueous extract filters to be collected, residue is standby;
(5), to get Spica Prunellae, Semen Litchi and step (4) residue obtained, adds 8-10 times of water gaging, decocts twice, 1-3 hour for the first time, 1-2 hour for the second time, extracting liquid filtering merged, add step (4) obtained aqueous solution, be condensed into the clear paste that relative density is 1.20-1.25, standby;
(6), get Talcum, succinum, be ground into 100 order fine powders, standby;
Step (2) gained clear paste, step (3) gained clear paste, step (4) gained volatile oil, step (5) gained clear paste and step (6) gained fine powder constitute the active component of Chinese medicine composition of the present invention jointly.
7, according to the arbitrary described application of claim 1-5, the preparation formulation that it is characterized in that described Chinese medicine composition is capsule, tablet, oral liquid or pill.
8,, it is characterized in that it is made up of following steps according to the preparation method of the described medicine capsule of claim 7:
(1), take by weighing Chinese crude drug, clean respectively, pulverize by the crude drug part by weight;
(2), get the Radix Astragali, Cortex Phellodendri, add 50-70% ethanol, heating and refluxing extraction 1-3 time, each 0.5-2 hour, extracting liquid filtering merged, and behind the decompression recycling ethanol, is condensed into the clear paste that relative density is 1.20-1.25, vacuum drying, dried cream is standby;
(3), get Fructus Ligustri Lucidi, add 6-10 and doubly measure 70-90% ethanol, heating and refluxing extraction 1-3 time, the time is each 1-3 hour, extracting solution filters, and merges, and behind the decompression recycling ethanol, is condensed into the clear paste that relative density is 1.20-1.25, vacuum drying, dried cream is standby;
(4), get Cortex Cinnamomi, add 4-8 times of water gaging and soak after 1-2 hour, extracted volatile oil 2-6 hour, volatile oil device is in addition collected, aqueous extract filters to be collected, residue is standby;
(5), it is residue obtained to get Spica Prunellae, Semen Litchi and step (4), add 8-10 times of water gaging, decoct twice, 1-3 hour for the first time, 1-2 hour for the second time, extracting liquid filtering, merge, add step (4) obtained aqueous solution, be condensed into the clear paste that relative density is 1.20-1.25, vacuum drying, it is standby that institute gets dry extract and gets dry extract with step (2), step (3) mixed powder that gets dry extract is broken into 100 order powder;
(6), get Talcum, succinum, be ground into 100 order powder, standby;
(7), with step (5) gained dried cream powder, step (6) gained fine powder and appropriate amount of auxiliary materials mix homogeneously, be binding agent with 80% ethanol, granulate oven dry, granulate;
(8), sift out fine powder, spray into step (4) gained volatile oil, airtight, encapsulated with the granule mix homogeneously, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810116116 CN101618103B (en) | 2008-07-03 | 2008-07-03 | Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810116116 CN101618103B (en) | 2008-07-03 | 2008-07-03 | Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101618103A true CN101618103A (en) | 2010-01-06 |
| CN101618103B CN101618103B (en) | 2012-02-15 |
Family
ID=41511631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810116116 Active CN101618103B (en) | 2008-07-03 | 2008-07-03 | Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101618103B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225035A (en) * | 2013-06-19 | 2014-12-24 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating male infertility |
| CN104225036A (en) * | 2013-06-19 | 2014-12-24 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of drug for treating urinary system infection |
| CN104225034A (en) * | 2013-06-19 | 2014-12-24 | 河北以岭医药研究院有限公司 | Application of composition in preparation of medicine for treating noninfectious urethral syndrome |
| CN104225033A (en) * | 2013-06-15 | 2014-12-24 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatic cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323689C (en) * | 2004-11-24 | 2007-07-04 | 河北以岭医药研究院有限公司 | Medicine for treating prostatic accrementition and its preparation |
-
2008
- 2008-07-03 CN CN 200810116116 patent/CN101618103B/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225033A (en) * | 2013-06-15 | 2014-12-24 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatic cancer |
| CN104225033B (en) * | 2013-06-15 | 2019-02-01 | 石家庄以岭药业股份有限公司 | A kind of application of Chinese medicine composition in preparation treatment prostate cancer drug |
| CN104225035A (en) * | 2013-06-19 | 2014-12-24 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating male infertility |
| CN104225036A (en) * | 2013-06-19 | 2014-12-24 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of drug for treating urinary system infection |
| CN104225034A (en) * | 2013-06-19 | 2014-12-24 | 河北以岭医药研究院有限公司 | Application of composition in preparation of medicine for treating noninfectious urethral syndrome |
| CN104225034B (en) * | 2013-06-19 | 2020-01-21 | 河北以岭医药研究院有限公司 | Application of composition in preparing medicine for treating non-infectious urethral syndrome |
| CN104225036B (en) * | 2013-06-19 | 2020-01-21 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating urinary system infection |
| CN104225035B (en) * | 2013-06-19 | 2020-01-21 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating male infertility |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101618103B (en) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101618110B (en) | Application of Chinese medicinal composition in preparing medicament for treating urinary calculi | |
| CN101683420B (en) | Applications of traditional Chinese medicine composition in preparation of medicament for treating acute pharyngitis | |
| CN101618103B (en) | Application of Chinese medicinal composition in preparing medicament for treating chronic glomerulonephritis | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN101564458A (en) | Application of Chinese medicinal composition in preparing medicament for treating bronchitis | |
| CN101683422B (en) | Applications of traditional Chinese medicine composition in preparation of medicament for treating cough variant asthma | |
| CN101607058B (en) | Application of Chinese medicinal composition in preparing medicament for treating chronic nephritis | |
| CN101653550B (en) | Chinese medicinal composition in preparation of medicament for treating type II diabetes | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN104000938B (en) | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN102247515B (en) | Traditional Chinese medicine compound preparation used for treating diabetic nephropathy, and preparation method thereof | |
| CN101637531B (en) | Application of Chinese medicinal composition in preparation of medicament for treating acute nephritis | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN101653489B (en) | Application of Chinese medicinal composition in preparation of medicament for preventing diabetes | |
| CN101632729B (en) | Application of Chinese medicinal composition in preparing medicament for treating involution syndrome | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN104306937A (en) | Pig gall and earthworm asthma-relieving tablet | |
| CN105434982A (en) | Chronic nonbacterial prostatitis treating pharmaceutical composition | |
| CN101439116B (en) | Use of Chinese medicinal composition in preparing medicament for treating diabetes mellitus induced erectile dysfunction | |
| CN101637530B (en) | Application of Chinese medicinal composition in preparation of medicament for treating urticaria | |
| CN104587030A (en) | Pharmaceutical composition for treating ureteral calculi and application of pharmaceutical composition | |
| CN114053386A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN115040622A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN101564438B (en) | Application of Chinese medicinal composition in preparation of medicament for treating acute severe brain injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |